Targovax ASA: Announcement of third quarter 2018 financial results

Oslo, Norway, 26 October 2018 – Targovax ASA (OSE: TRVX, Targovax), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its third quarter 2018 results on Thursday, 1 November 2018 at 07:00 CET.

The results report, and the presentation will be available at www.targovax.com in the investors section from 07:00 CET.

Øystein Soug, Chief Executive Officer of Targovax, will host an online presentation for investors, analysts and the press at 08:45 CET. The presentation can be followed here, or at: https://www.facebook.com/AXExposure/videos/279295392691286/

For an elaborate presentation of the Targovax strategy, please visit targovax.com for a replay of the 15 October 2018 Capital Markets Day.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.